The HOPE Study: Characterizing Patients With Hepatitis B and C

Who May Qualify: 1. At least 18 years old 2. Hepatitis B and/or C-infected; or history of hepatitis B infection, but cleared; or hepatitis C infection and successfully treated with direct acting antiviral agents, with or without HIV infection; or healthy volunteer without history of HBV and/or C, nor HIV 3. Willing to have samples stored for future research 4. Must have an identifiable primary care provider or be in the process of establishing a primary care provider 5. Willing to undergo HIV testing if not recently documented 6. Inclusion in the HBV treatment sub-study will be dependent on eligibility to receive nucleos(t)ide analogue therapy according to standard-of-care. Who Should NOT Join This Trial: 1. Unable to comply with research study visits 2. Poor venous access not allowing screening laboratory collection 3. Have any condition that the investigator considers a contraindication to study participation. 4. HBV monoinfected participants with any contraindications to HBV treatment with nucleos(t)ide analogues will be ineligible to participate in the HBV treatment sub-study. 5. Pregnant or breastfeeding women will not be eligible to participate in the HBV treatment sub-study Always talk to your doctor about whether this trial is right for you.